Type 11 and Type 12 OTC derivatives licensing status

What Type 11 and Type 12 cover

Type 11 is dealing in OTC derivative products or advising on OTC derivative products. Type 12 is providing client-clearing services for OTC derivative transactions. The activities were created as part of Hong Kong’s OTC derivatives regulatory framework and appear in Schedule 5 of the SFO.

The definitions describe activities, not product names alone. A firm must examine whether it deals in, advises on, clears, manages, or provides trading services for OTC derivatives. Other existing regulated activities, including Types 7 and 9, may also apply to parts of an OTC business.

The current licensing status

The SFC’s current “Do you need a licence or registration?” page lists Types 11 and 12 with a note that they are not yet in operation for licensing purposes. The Licensing Handbook contains the same status note. A candidate should therefore distinguish statutory inclusion from commencement of the licensing requirement.

This status can change through a commencement notice or regulatory update. Always check the current SFC page and legislation before advising on a live business. An article or course note should carry a verification date, because the “not yet in operation” status is time-sensitive.

Existing OTC rules are already in force

The non-commencement of Type 11/12 licensing does not mean Hong Kong has no OTC derivatives regulation. Mandatory reporting, recordkeeping, and clearing obligations have been introduced in stages. The SFC and HKMA list rules, notices, and commencement dates for those obligations.

For example, reporting of certain interest-rate swaps and non-deliverable forwards began in 2015 and was expanded to key asset classes in 2017; clearing obligations for specified standardized interest-rate swaps commenced in 2016 and were later amended. These duties are separate from a new licensing permission.

Other regulated activities can still apply

A firm may already need a Type 2, Type 7, or Type 9 licence or registration for its existing OTC-related business, depending on what it does. The SFC has described expanded scope for automated trading services and asset management. Do not treat the Type 11/12 non-commencement note as a general exemption from all SFO requirements.

Authorized institutions and certain other market participants can be supervised under the Banking Ordinance or specific exemptions. The activity, entity, product, and client arrangement determine the regime. The SFC and HKMA may have different supervisory roles for the same market participant.

How commencement would affect firms

When the licensing regime commences, entities conducting covered dealing, advice, client clearing, or expanded activities may need new permissions or transitional relief. The framework contemplates notification and transitional arrangements for firms already undertaking relevant activities. Firms should inventory contracts, clients, trading systems, and staff responsibilities in advance.

The SFC has continued work on the OTC derivatives regime, including 2026 communications and consultations on related controls. But a consultation or webinar is not itself commencement. Check for a gazetted date and official notice before treating a new licensing duty as active.

Exam distinction: activity, licence, and market rules

The exam may ask about what the types are, whether the licensing requirement is in force, and what other OTC obligations already apply. These are three separate questions. A statutory activity can exist while its licensing commencement remains pending; reporting and clearing rules can still operate meanwhile.

Answer in sequence: name the activity, state the current SFC licensing status, then identify other current regulatory duties if relevant. Do not infer a licensing launch date from a consultation schedule or a notice about clearing thresholds.

Verification checklist

Before relying on the status, check the SFC licensing page, the current Licensing Handbook, the OTC derivatives regime page, and any Gazette commencement notice. Confirm whether a more recent SFC circular has changed the relevant activity or added transitional dates.

For the exam, prioritize the currently published syllabus materials, but be ready to identify that Type 11 and Type 12 are not yet operational for licensing if that remains the SFC’s stated position. For a real firm, seek current compliance advice because launch dates and exemptions may evolve.

Do not confuse licensing status with the OTC regime

The SFC’s licensing page currently labels Types 11 and 12 as not yet in operation for licensing purposes. Type 11 concerns dealing in OTC derivative products; Type 12 concerns providing client clearing services for OTC derivative transactions. This status is about whether the new activity categories are open for licensing, not whether OTC derivatives are unregulated.

Hong Kong’s OTC derivatives regime already imposes reporting and clearing obligations in stages on relevant entities and transactions. A firm should assess those obligations separately from whether it needs a Type 11 or Type 12 licence. Entity type, transaction category, counterparty status, thresholds, and any exemption can determine whether reporting or clearing applies.

Use a two-column compliance analysis

For a scenario, write “licensing” in one column and “reporting/clearing” in the other. Under licensing, check the SFC’s current activity status and the firm’s existing permissions. Under the OTC regime, check whether the transaction and counterparties fall within a reporting or clearing obligation that has commenced.

This prevents the mistaken conclusion that no OTC compliance is required because a Type 11 or Type 12 licence is not yet operational. It also avoids implying that every OTC derivative transaction is subject to the same requirement: the rules are phased and include thresholds and exemptions. Confirm the latest SFC notices before applying dates or scope.

Types 11 and 12 appear in the statutory framework for OTC derivatives, but the SFC’s licensing materials state their commencement or implementation status separately. A regulated-activity definition in the SFO does not necessarily mean a firm can apply for, or must already hold, that licence today. Check the SFC’s current “Do you need a licence” page and latest circulars before describing the live position; do not rely on an old exam note.

Other OTC obligations can already apply

The licensing status of Types 11 and 12 is separate from obligations under the OTC derivatives regime, which may include reporting, clearing, recordkeeping, or risk-mitigation requirements for specified entities and transactions. Those duties have their own scope, thresholds, phases, and exemptions. A firm should map the legal entity, counterparty, product, and obligation rather than assume that no licence means no regulation.

Example and exam takeaway

A firm arranges an OTC derivatives transaction and asks whether it needs a Type 11 or Type 12 licence. The answer must distinguish the SFC’s stated licensing commencement position from any reporting or clearing obligation that already applies to the firm. For an exam, identify the date of the question, the particular licence category, and the separate OTC regime duty. Confirm current status from the regulator rather than treating a future statutory category as already operative.